Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer

• मुख्य लेखकों: Dantong Sun (लेखक), Lu Tian (लेखक), Yan Zhu (लेखक), Yang Wo (लेखक), Qiaoling Liu (लेखक), Shihai Liu (लेखक), Hong Li (लेखक), Helei Hou (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: BMC, 2020-08-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Abstract Introduction Patients with advanced non-small cell lung cancer (NSCLC) benefit from treatment with immune checkpoint inhibitors (ICIs). Biomarkers such as programmed death-ligand 1 (PD-L1), the tumor mutational burden (TMB) and the mismatch repair (MMR) status are used to predict the progno...